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CASE REPORT

Cinacalcet as Adjunctive Therapy for Hereditary
1,25-Dihydroxyvitamin D–Resistant Rickets
Tarak Srivastava and Uri S Alon
Section of Nephrology, Bone and Mineral Disorder Clinic, Children’s Mercy Hospitals and Clinics, University of Missouri at Kansas City,
Kansas City, MO, USA

ABSTRACT
Secondary hyperparathyroidism from inadequate calcium absorption in the gut, is the underlying pathophysiology for rachitic changes
in hereditary vitamin D–resistant rickets (HVDRR). We describe a novel use of Cinacalcet to treat a child with HVDRR in whom
conventional modes of therapy had to be discontinued. Cinacalcet therapy with high-dose oral calcium effectively normalized the
metabolic abnormalities and bone condition. The relative ease of administration of the calcimimetic as a once- or twice-daily oral
preparation, compared with traditional intravenous calcium administration, should encourage its move to the frontline of treatment of
the disorder. ß 2013 American Society for Bone and Mineral Research.
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Introduction

Case Report

H

A 13-month-old male child was brought to the hospital for
evaluation of failure to thrive. At presentation, his weight
was 8.025 kg (Z-score –4.8) and length 65 cm (Z-score –2.6). He
had rachitic rosary over the chest wall, widening of wrists
and ankles, and bowing of upper and lower extremities. His
head appeared disproportionately large (head circumference
51 cm, Z-score 3.2) with open anterior fontanel and frontal
bossing. He had patches of scalp that were devoid of hair,
whereas other regions had sparse hair, and scant eyebrows.
He also exhibited delayed dentition, a large umbilical hernia,
and generalized developmental delay. At presentation, his
serum chemistry panel showed normal serum electrolytes,
albumin, magnesium, BUN, and creatinine. Serum calcium
(Ca) was 7.4 mg/dL, iCa 0.96 mmol/L (normal 1.13 to 1.37),
phosphorus (P) 2.4 mg/dL, parathyroid hormone (PTH) 1103 pg/mL,
and alkaline phosphatase (ALP) 893 U/L (Table 1). His serum
25(OH)-D3 concentration was 15 ng/mL and 1,25(OH)2-D3
200 pg/mL. The skeletal survey showed generalized osteopenia
with advanced features of rickets manifested by cupping
and fraying at the metaphyseal ends of long bones of
upper and lower extremities, and widening of growth
plates (Fig. 1C). Kidney ultrasound showed no evidence of
nephrocalcinosis.

ereditary vitamin D–resistant rickets (HVDRR) is a rare
autosomal recessive disease (OMIM 277440), and is
characterized by early-onset rickets, hypocalcemia, hypophosphatemia, and secondary hyperparathyroidism in the face of
elevated serum 1,25(OH)2-D3 concentration.(1–3) A subset of
children have total/partial alopecia and dermal cysts.(1–3) The
disorder results from loss of function mutation in vitamin
D–receptor (VDR) gene, leading to target organ resistance to
1,25(OH)2-D3.(1) Several mutations have been described, and
individuals with alopecia are generally unresponsive to oral
calcium and 1,25(OH)2-D3 therapy, and are currently being treated
with intravenous calcium via a central line.(4–7) Secondary
hyperparathyroidism from inadequate calcium absorption in
the gut, is the underlying pathophysiology for rachitic changes in
HVDRR.(8) Preliminary studies showed the calcimimetic Cinacalcet to be safe and effective therapy in children with secondary
hyperparathyroidism, as a result of other conditions, such as
renal failure, X-linked hypophosphatemic rickets (XLH), and
familial hypocalciuric hypercalcemia.(9–12) In this report, we
describe our novel experience with Cinacalcet therapy in a child
with HVDRR that is resistant to 1,25(OH)2-D3, as a result of a
missense mutation affecting the DNA-binding domain of VDR, in
which all other modes of therapy were exhausted.
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Table 1. Effect of Therapy With Elemental Calcium, Ergocalciferol, Calcitriol, and Cinacalcet Over Four Time Periods on Serum Total
Calcium, Phosphorus, Parathyroid Hormone, and Alkaline Phosphatase

Age (months)

13
15
17
18
18
19
Median for the period
Mean for the last three visits
20
21
22
23
24
25
26
27
Median for the period
Mean for the last three visits
28
30
32
33
34
36
38
40
42
44
46
48
49
Median for the period
Mean for the last three visits
51
52
54
56
58
60
62
64
66
68
70
Median for the period
Mean for the last three visits

Elemental Calcium Ergocalciferol Calcitriol Cinacalcet Serum Ca Serum P Serum ALP Serum PTH
(mg/day)
(units/day) (mg/day) (mg/day) (mg/dL) (mg/dL)
(U/L)
(pg/mL)
Reference Range
8.6–10.5 3.5–6.8
Period I: Oral Treatment with Vitamin D, Calcium, and Calcitriol
0
0
0
7.4
2.4
800
8000
0.4
8.4
2.8
1600
800
1
8.6
2
2400
800
1.5
7.3
2.1
4000
800
6
8.6
2.2
8000
800
6
7.8
2.9
7.8
2.4
7.9
2.4
Period II: Treatment with Intravenous Calcium
550 mg over 10 hrs
400
0
7.8
2.9
600 mg over 10 hrs
400
0
8.3
2.2
450 mg over 15 hrs
400
0
8.2
2.8
400 mg over 20 hrs
400
0
8.5
5.0
400 mg over 20 hrs
400
0
9.0
4.0
400 mg over 20 hrs
400
0
9.2
6.6
400 mg over 20 hrs
400
0
8.8
4.9
400 mg over 20 hrs
400
0
9.1
5.9
8.5
4.0
9.0
5.8
Period III: Off Intravenous Calcium Therapy
None
400
0
8.9
4.9
None
400
0
8.7
4.5
None
400
0
9.3
5.5
1800
400
0
9.0
4.9
2400
400
0
9.1
5.4
3000
400
0
8.8
4.0
3000
400
0
8.9
4.7
3000
400
0
8.9
3.7
3750
400
10
8.9
3.0
3750
400
10
8.5
3.7
3750
400
10
9.0
3.4
3750
400
20
8.9
3.5
3750
400
20
9.2
4.0
8.9
4.5
9.0
3.6
Period IV: Novel Therapy with Cinacalcet
3750
400
20
09
8.5
3.5
3750
400
20
18
8.2
4.4
4500
400
20
16
8.8
5.0
4500
400
20
16
8.3
5.4
6000
400
20
16
8.0
5.1
6000
400
20
16
7.9
4.6
6000
400
20
16
8.4
4.8
6000
400
0
16
8.7
6.7
6000
400
0
08
9.4
6.0
6000
400
0
08
9.3
4.1
6000
400
0
08
8.7
4.0
8.4
4.5
9.1
4.7

110–320

7–75

893
1165
920
529
725
485
725
580

1103
641
1055
1147
642
895
815
895

851
1039
805
532
348
383
332
294
432
336

799
360
158
193
99
94
136
115
165
115

256
277
392
382
370
379
522
556
547
530
520
490
508
460
506

59
172
239
92
134
218
496
412
479
530
375
545
516
268
479

387
332
345
272
251
230
209
246
225
178
286
280
230

423
378
148
85
77
108
72
113
84
12
9
122
35

Serum creatinine and albumin concentrations remained normal for age throughout these periods.
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Fig. 1. The clinical course of the child with HVDRR has been divided into four periods based on key therapies during each period. The locally weighted
regression-smoothing scatter plot (LOESS) regression, based on the Epanechnikov kernel function and piecewise change-point regression model, was
used to best fit the data for serum PTH, ALP, Ca, and P. (A) Scatter plot for serum parathyroid hormone (PTH) and serum alkaline phosphatase (ALP).
Individual results of serum PTH are represented by (*) and LOESS regression line by (–), and of serum ALP by (~) and LOESS regression line by (---). (B)
Scatter plot for serum calcium (Ca) and serum phosphorus (P). Individual results of serum Ca are represented by (*) and LOESS regression line by (–), and
for serum P by (~) and LOESS regression line by (---). (C) Radiological changes over the four time periods. Period I: Oral treatment with vitamin D, calcium,
and calcitriol, during which the child had received ergocalciferol and escalating doses of calcium and calcitriol with minimal/poor response to therapy, as
shown by persistent marked elevation in serum PTH and ALP; low serum P concentration; and rachitic changes on X-rays. Period II: Treatment with
intravenous calcium for HVDRR, during which the child achieved almost normalization of serum PTH, ALP, Ca, and P, and healing of rachitic changes on Xray. Period III: Off intravenous calcium therapy because of recurrent line infections/sepsis. The child received high oral dose of calcium and, subsequently,
extremely high doses of calcitriol therapy, which could not prevent slow deterioration of his mineral metabolism and recurrence of early changes of rickets
on X-ray. Period IV: Cinacalcet combined with oral calcium therapy led to normalization of all biochemical parameters with complete healing of rickets.

Period I: Oral treatment with vitamin D, calcium,
and calcitriol
To eliminate the possibility of nutritional rickets, the child was
initially treated with standard doses of ergorcalciferol, calcium,
and calcitriol (Table 1). However, even after normalization of
25(OH)-D3 level, there was no evidence of healing of rickets on
X-rays, nor correction of serum Ca, P, ALP, and PTH levels. Next,
an attempt was made to treat with incrementally increasing
supra-physiological doses of calcium and calcitriol reaching
elemental calcium of 8000 mg/day and calcitriol 6 mg/day.
During this 6 months of oral therapy, his 25(OH)-D3 levels rose
to 117 ng/mL and 1,25(OH)2-D3 to 669 pg/mL, but no improvement on X-rays was observed, and the child’s chemistry panel
continued to show unresponsiveness. Toward the end of this
period we evaluated him for VDR gene mutation. A single G to A
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missense mutation was identified in exon 2 that changed the
codon for valine to methionine at amino acid 26 (V26M) in the
DNA-binding domain confirming the diagnosis of HVDRR.(13)
The functional impact of this mutation has been previously
described.(13)

Period II: Treatment with intravenous calcium
Once HVDRR was confirmed, and with family’s consent, we
embarked on intravenous calcium therapy. Calcium gluconate
was initiated at 550 mg of elemental calcium daily, infused via a
central line over a period of 10 hours. Over the next 8 months, the
dose of calcium was titrated based on biochemical response,
ranging between 450 and 600 mg per day, infused over 10 to
20 hours. He responded to treatment with significant improvement, albeit not complete normalization, of his serum Ca, P, ALP,
Journal of Bone and Mineral Research

and PTH, and radiological healing of rickets (Table 1 and Fig. 1A–
C. During this period, 25(OH)-D3 levels ranged between 33
and 47 ng/mL and 1,25(OH)2-D3 between 99 and 243 pg/mL.
However, intravenous calcium therapy was complicated by
repeated severe central-line infections with various organisms,
including Serratia, Citrobacter, Enterobacter, Enterococcus, and
Staphylococcus species that failed to respond to conventional
antibiotic therapy, each time necessitating central-line removal
and replacement. An extensive work-up failed to detect any
immunological malfunction. After the seventh life-threatening
line infection, we agreed with the family to discontinue
intravenous treatment.

1412 nmol/mmolCr (normal 56 to 1763). They decreased to
78.9 mg/L, 29 ng/mL, and 530 nmol/mmolCr, respectively, on last
follow-up. Serum FGF-23 was undetectable throughout this
period, while 25(OH)-D3 levels ranged between 38 and 64 ng/mL
(64 ng/mL on last follow-up), and 1,25(OH)2-D3 ranged between
246 and 2630 pg/mL (246 ng/mL on last follow-up). On last follow
up the patient’s weight was 20.7 kg (Z-score 0.1), length 102.3 cm
(Z-score –2.4); he had normal chemistries, resolution of rachitic
changes and no nephrocalcinosis, but no change in alopecia.

Period III: Off intravenous calcium therapy

HVDRR results from loss of function of VDR leading to target
organ resistance to 1,25(OH)2-D3.(1) The nature of the mutation
impacts alopecia and response to therapy.(1) As described before,
in vitro studies on our patient’s fibroblasts revealed that the
mutant V26M VDR failed to induce CYP24A1 gene in response to
treatment with up to 1000 nM 1,25(OH)2-D3.(13) Indeed, as was
found in period I, and again while on extremely high oral doses
of elemental calcium (200 to 250 mg/kg/day) and calcitriol
20 mg/day in period III, there was no improvement in the
patient’s biochemical and radiological abnormalities, indicating
complete resistance to 1,25(OH)2-D3, similar to other children
with alopecia and mutation in the DNA-binding domain.(1)
Recently Tiosano and Hochberg have proposed a mechanistic
classification of rickets, namely PTH-dependent, FGF 23–
dependent, and Renal, all leading to a common denominator
of hypophosphatemia causing rickets by interfering with
apoptosis of chondrocytes.(8) They proposed HVDRR to be a
form of PTH-dependent rickets. The secondary hyperparathyroidism develops because of decreased gastrointestinal calcium
absorption and leads to both hypophosphatemia and increased
bone turnover, as was evident in our patient while he was off
effective treatment (Table 1). In HVDRR the defect in calcium
absorption can be overcome by intravenous calcium infusion,
which bypasses the gut.(4–7) We could replicate this observation
in period II, when the child received intravenous calcium therapy
resulting in marked, albeit incomplete, reversal of the biochemical and skeletal abnormalities. The fulminant life-threatening
infections led to a comprehensive immunological workup, which
failed to detect any abnormality and consequently resulted in
withdrawal of this line of therapy.
In period III, we attempted to maximize the use of vitamin D–
independent, nonsaturable paracellular pathway of calcium
absorption in the gut by supplementing our patient with 200 to
250 mg/kg/day of oral calcium, in spite of which there was a slow
and steady worsening of his mineral and skeletal status (Table 1
and Fig. 1A–C). Thus, because of circumstances beyond our
control, period III resulted in an ineffective treatment providing a
‘‘washout’’ period between periods II and IV.
The VDR mutation causing HVDRR results in poor calcium
absorption from the gut.(15) Based on the concept that skeletal
pathophysiology is a form of PTH-dependent rickets, which
develops in response to the poor absorption of calcium in the
gut, we considered the use of a calcimimetic as a mean to
normalize serum PTH. The safety and efficacy of Cinacalcet in
children has been shown in a few small series and anecdotal

After discontinuation of intravenous calcium therapy, and while
on maintenance dose of 400 units of ergocalciferol, we observed
a gradual increase in ALP and PTH despite normal serum calcium
levels (Table 1). The addition of high-dose of oral calcium did
not affect the trend of rising ALP and PTH, and decline in serum P.
It was evident that the improvement achieved previously with
intravenous calcium therapy was slowly dissipating by increasing
severity of secondary hyperparathyroidism, and therefore
calcitriol at highly supra-physiological doses was added.(14)
However, after 20 months of this mode of treatment, no
significant impact on serum levels of ALP and PTH could be
observed, and X-rays showed increased flaring and cupping of
the metaphyses consistent with early manifestations of rickets.
Serum 25(OH)-D3 levels ranged between 32 and 52 ng/mL, and
1,25(OH)2-D3 level ranged between 129 and 2430 pg/mL during
this period. FGF-23 was undetectable.

Period IV: Cinacalcet therapy
After a thorough discussion with the family, a decision was made
to try Cinacalcet as part of the child’s treatment. Although the
manufacturer does not recommend crushing the tablet, having
no other choices of how to administer it, we prepared a
suspension daily by crushing 30 mg tablet into 10 mL water. The
treatment was started in the hospital for close monitoring of
serum iCa, because of the possibility of hypocalcemia induced by
Cinacalcet therapy. The starting dose of Cinacalcet was 4 mg
(0.25 mg/kg) once a day. We did not appreciate a significant
decrease in serum iCa, and the dose was incrementally increased
based on serum PTH levels, reaching 4.5 mg twice a day by the
end of the week, when the child was discharged. The dose was
further increased over the next 6 weeks to 9 mg twice a day
(1 mg/kg/day) as an outpatient. Over the next year, we
observed sustained control of secondary hyperparathyroidism
and healing of the patient’s rachitic changes on X-rays (Table 1
and Fig. 1A–C. At the age of 62 months, calcitriol therapy
was discontinued. Nevertheless, the patient continued to
maintain normal values of all biochemical parameters and
normal-appearing bones on radiographs, and consequently
the Cinacalcet dose was decreased to once a day at 8 mg
(0.4 mg/kg/day) (Table 1). The bone turnover markers obtained
before the initiation of Cinacalcet therapy were elevated; namely
Bone Specific-ALP was 187.1 mg/L (normal 25 to 124), osteocalcin
was 48 ng/mL (normal 9 to 38), and urine N-telopeptide was
Journal of Bone and Mineral Research
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cases of secondary hyperparathyroidism in other disorders.(9–12).
Because of the concern that Cinacalcet therapy might cause
hypocalcemia, the high dose of oral calcium supplementation
was not interrupted. However, because of the potential adverse
effect of sequestration of dietary phosphate in the gut, we
recommend that future studies try to use lower doses of
supplementary calcium. Supplementation with phosphate was
not necessary because serum phosphate normalized with
suppression of the parathyroid gland with either intravenous
calcium or Cinacalcet therapy (Table 1 and Fig. 1).(2,3,15–17)
Cinacalcet exerted its effect rapidly, resulting in suppression of
PTH and resolution of the radiological changes of rickets.
This effect was further corroborated by suppression of bone
turnover markers, and also by an apparent increase in bone
mineralization on X-rays. Not unexpected, the beneficial effect of
the calcimimetic agent was unaffected by the discontinuation of
supplementation with 1,25(OH)2-D3. We did not observe any
difficulties in the preparation or administration of the medication
to the young child.
The patient described in this report exhibited the classical
clinical pattern of HVDRR from a VDR mutation that caused
complete target organ resistance to 1,25(OH)2-D3. The successful
treatment with Cinacalcet shows that the skeletal pathophysiology of rickets in HVDRR is PTH dependent, and that successful
control of the secondary hyperparathyroidism is sufficient to
heal the rickets, even though resistance to 1,25(OH)2-D3 remains
unaffected. Considering its relative easiness of the administration as a once-a-day or twice-a-day oral preparation, compared
with the cumbersome and at times risks-associated intravenous
calcium therapy, one can consider Cinacalcet to be an adjunct
to calcium therapy in management of children with HVDRR.
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